Center-Authored Papers

Filters: Author is Metch, Barbara  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G et al..  2013.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.. Journal of acquired immune deficiency syndromes (1999). 63(2):239-44. Abstract
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
VACCINIA VIRUS
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
Vaccines, Subunit
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Vaccine and Infectious Disease Institute
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Vaccine and Infectious Disease Division
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G et al..  2013.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.. Journal of acquired immune deficiency syndromes (1999). 63(2):239-44. Abstract
Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa J-P, Abdul-Jauwad H, Adbul-Jauwad H, Joseph P, Koenig E et al..  2013.  Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition.. AIDS (London, England). 27(11):1763-70. Abstract
Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M et al..  2012.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults.. PloS one. 7(1):e29231. Abstract
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR.  2010.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.. JAMA : the journal of the American Medical Association. 304(3):275-83. Abstract
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
Vaccination
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
Unsafe Sex
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G et al..  2013.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.. Journal of acquired immune deficiency syndromes (1999). 63(2):239-44. Abstract
United States
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G et al..  2013.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.. Journal of acquired immune deficiency syndromes (1999). 63(2):239-44. Abstract
Treatment Outcome
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Time Factors
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
T-Lymphocytes, Cytotoxic
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Substance-Related Disorders
Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa J-P, Abdul-Jauwad H, Adbul-Jauwad H, Joseph P, Koenig E et al..  2013.  Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition.. AIDS (London, England). 27(11):1763-70. Abstract
Specimen Processing Core Facility
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
South America
Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa J-P, Abdul-Jauwad H, Adbul-Jauwad H, Joseph P, Koenig E et al..  2013.  Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition.. AIDS (London, England). 27(11):1763-70. Abstract
Shared Resources
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract